Volume: 7 Issue: 1
Year: 2019, Page: 99-100,
Introduction: Hyperammonemic encephalopathy secondary to Valproate therapy is an uncommon adverse affect. We had a 70year old female, known case of epilepsy on sodium Valproate form 3 years presented with drowsiness, slurring of speech. Investigations were done Magnetic resonance imagingBrain and Liver Function Tests were normal, Serum Valproate and Serum Ammonia levels were increased. Valproate was withdrawn and patient was started on L – Carnitine. Serum Ammonia levels decreased and patient symptoms subsided. Hyperammoneic Encephalopathy should be suspected in patients on Valproate presenting with Encephalopathy symptoms.
Keywords: HyperammonemicEncephalopathy, Sodium Valproate, Epilepsy, L- carnitine, Serum Ammonia.
1. Steward J T. A case of hyperammonemic encephalopathy after 11 years of valproate therapy. J Clin Psycho pharmacol 2008;28:361-2.
2. Tarafdar S, Slee M, Ameer F, Doogue M. A case of valproate induced hyperammonemic encephalopathy. Case Reports in Medicine 2011; 2:100-102.
3. Chopra A, Kolla BP, Mansukhani MP, et al. Valproateinduced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management. Gen Hosp Psychiatry 2012;34(3):290-298.
4. Tarafdar S, Slee M, Ameer F, Doogue M. A case of valproate induced hyperammonemicencephalopathy. Case Report Med 2011; 3:505.
5. De Wolfe JL, Knowlton RC, Beasleys MT. Hyperammonia following intravenous Valproate loading. Epilepsy research 2009;85: 65-71.
Anusha K, Jayakumar P, Kishan Reddy H. Hyperammonemic encephalopathy secondary to chronic Valproicacid overdose. Perspectives in Medical Research 2019; 7(1):99-100.